Fannie Mae, Freddie Mac shares tumble after conservatorship comments
LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a biotechnology company specializing in viral disease diagnostics with a current market capitalization of $5.56 million, has initiated patient enrollment for a UK-based clinical study. The study is a collaborative effort with the National Health Service to evaluate the performance of the ViraxImmune™ FluoroSpot T cell assay in detecting T cell dysfunction in individuals with post-acute infection syndromes such as long COVID, post-treatment Lyme disease, and myalgic encephalomyelitis/chronic fatigue syndrome.
The study, which aims to enroll up to 200 participants, is part of the regulatory approval process, with initial findings expected in the second quarter of 2026. CEO James Foster highlighted the lack of reliable diagnostics for these conditions and expressed that the data from this clinical study would contribute to understanding immune dysregulation, thereby improving diagnostics and patient care. According to InvestingPro data, analysts anticipate a significant revenue growth forecast of 50.66% for the current fiscal year, though the company remains in its development phase.
Virax Biolabs is developing T cell-based testing technologies intended to offer an immunology profiling platform, which could be particularly beneficial in diagnosing and treating post-viral syndromes and other chronic conditions associated with immune dysregulation. While the company maintains a strong liquidity position with a current ratio of 11.58 and more cash than debt on its balance sheet, InvestingPro analysis indicates the company is currently burning through cash rapidly. For detailed financial health metrics and 13 additional ProTips, consider exploring InvestingPro’s comprehensive analysis platform.
This press release includes forward-looking statements based on current expectations and projections about future events. These statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially from those projected. The company emphasizes that the forward-looking statements are predictions and may not reflect actual future events.
The information provided in this article is based on a press release statement from Virax Biolabs.
In other recent news, Virax Biolabs Group Limited has revealed research findings on T-Cell dysfunction in post-acute infection syndromes at the World Immune Regulation Meeting in Davos. The study highlights the role of T-Cell exhaustion due to chronic infections like SARS-CoV-2, indicating diminished immune functionality. Virax’s preliminary results from their ViraxImmune™ PAIS assay show significant cytokine level changes in PAIS patients, which could enhance diagnosis and treatment for conditions such as long COVID. In a separate development, Virax Biolabs is aligning with U.S. vaccine transparency efforts by providing data-driven insights into vaccine efficacy and individual immune profiles. This initiative is part of the company’s strategy to support public health initiatives and enhance research in protective immunity. Additionally, Cosmos Health Inc. has expanded its distribution agreement with Virax Biolabs to include all Gulf Cooperation Council countries for the distribution of Avian Influenza Virus Real-Time PCR Kits. This expanded agreement aims to support public health initiatives in the region. These developments reflect Virax Biolabs’ ongoing efforts to advance immune response detection and contribute to public health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.